Home/All Molecules/Ramipril

Ramipril Range

Comprehensive Ramipril portfolio for Franchise & Manufacturing.

Category
ramipril
Total Formulations
11
Available Forms
Capsule, Tablets

Expand Your Business with Our Multiple Divisions


Browse Ramipril portfolio by Dosage Form


The Cafoli Advantage for PCD Franchise & Manufacturing

WHO-GMP Quality

Every Ramipril batch undergoes rigorous in-house and third-party testing, strictly adhering to WHO-GMP standards for efficacy and safety.

Quality Policy

Monopoly & Branding

Secure exclusive PCD franchise rights for your territory and benefit from our range of premium, marketing-driven product packaging.

Market Strategy

Sales Support

Enhance your sales with Cafoli’s complete kit of marketing materials, including visual aids, MR bags, catch covers, and product cards.

Marketing Tools

Ramipril PCD Pharma Franchise

Ramipril PCD Pharma Franchise Company

Cafoli Lifecare is a WHO-GMP certified Ramipril PCD pharma franchise company offering a portfolio of 11 Ramipril formulations across tablets and capsules. Every batch is manufactured at DCGI-approved facilities and supplied to franchise partners with district-level monopoly rights, ready-to-use promotional inputs and dependable stock availability.

What is Ramipril?

Ramipril is a long-acting angiotensin-converting enzyme (ACE) inhibitor. Its active metabolite ramiprilat blocks the conversion of angiotensin I to angiotensin II, lowering vascular resistance and blood pressure while reducing aldosterone-driven sodium retention. The compound record can be reviewed on PubChem.

Therapeutic Applications

Essential hypertension, chronic heart failure, post-myocardial-infarction management, diabetic and non-diabetic nephropathy, and cardiovascular risk reduction in high-risk patients. It is commonly paired with hydrochlorothiazide or amlodipine in fixed-dose antihypertensive packs.

Prescribed by: Cardiologists, nephrologists, diabetologists and general physicians prescribe Ramipril; it is also a mainstay of primary-care hypertension management.

Why Ramipril is a High-Potential Molecule for Distributors

Hypertension therapy is lifelong, so an antihypertensive on a distributor list generates repeat monthly refills for years rather than a single course. Ramipril is one of the few ACE inhibitors carrying long-term cardiovascular outcome evidence behind its risk-reduction indication, which keeps it firmly in physician practice despite the broader shift toward ARBs. It is off-patent, made from readily available API, and can therefore be priced competitively while still supporting healthy trade margins across its eleven formulations.

Why Choose Cafoli Lifecare

Cafoli Lifecare offers its Ramipril franchise partners genuine monopoly rights for their allotted district or territory, products manufactured in WHO-GMP certified, DCGI-approved units, and complete promotional support — visual aids, MR bags, sample packs, product cards and doctor gifting. With 1000+ channel partners across India, on-time dispatch and transparent net rates, we make it straightforward to build a profitable Ramipril business in your region.

References

  1. PubChem – Ramipril compound record, US National Library of Medicine
  2. PubMed – clinical literature on Ramipril, NCBI
  3. WHO Model List of Essential Medicines

Aceclofenac in Modern Clinical Practice

Our formulations of Ramipril find application in many critical therapeutic areas. Its therapeutic spectrum includes, but is not limited to:


FAQ about Ramipril in PCD Franchise

Start Your Ramipril Franchise with Cafoli Lifecare

Ready to take monopoly rights for Ramipril in your district? Talk to our franchise team for net rates, packing details and the current availability list. Call 9518447302 or email info@cafoli.in.

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Frequently Asked Questions (FAQs)

Cafoli Lifecare offers 11 Ramipril formulations in tablets and capsules. The current list with packing and net rates is shared with registered franchise enquiries.

Yes. Monopoly rights for the Ramipril range are allotted district-wise on a first-come basis and are confirmed in your franchise agreement, so no other Cafoli partner sells the same brands in your territory.

Cardiologists, nephrologists, diabetologists and general physicians prescribe Ramipril; it is also a mainstay of primary-care hypertension management.

Ramipril is backed by long-term cardiovascular outcome evidence and remains a recognised choice for hypertension with diabetes, heart failure or nephropathy, where the aim is organ protection and not blood-pressure numbers alone. It is also markedly more affordable than most ARBs, which matters in lifelong therapy and makes it a dependable, high-repeat line for distributors.

You need a valid Drug License and a GST registration in your name. Once these are shared along with your territory preference, the Ramipril franchise agreement and monopoly allotment can be processed.